From: Mitotically active cellular fibroma of the ovary: a case report and literature review
Author | Year | Case no. | Age (y) | Side | Size(cm) | Tumor marker | Mitoses (MF/10HPF) | Surgery | Additional therapy | Positive | Weak, focally | Negative | ki-67 index | Follow-up time (mo) | Status at last follow-up |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kaku et al. [2] | 2007 | 1 | 32 | Left | 6.6 × 6,0 × 4.4 | CA 125(-), CEA(-) | 17 | LSO | - | SMA, HHF35, vimentin, PR, ki-67 | ER | desmin | ND | 12 | NED |
Bucella et al. [3] | 2009 | 2 | 65 | ND | 10(1st), 12 × 10 × 9 (2nd), 8 (3rd) | - | 4 | TAH, BSO, reduction twice | Tamoxifen | vimentin | α-inhibin, actin, CD99 | desmin, h-caldesmon, CD10, HMB-45, c-kit | 9 | 60 + 6 + 6 | Recurrence twice, NED |
Monterio et al. [4] | 2012 | 3 | 13 | Right | 19 × 15 × 12 | CA125(453), AFP(-), HCG(-), CEA(-), CA199(-), CA153(-) | 5–7 | RSO, OMT | - | ND | ND | ND | ND | 36 | NED |
Wu et al. [5] | 2014 | 4 | 76 | Right | 9 × 6 × 5 | CA125(-), CA153(-), CA199 (-),AFP (-), CEA(-), SCC(-) | 5–9 | TAH, BSO | - | vimentin, α-inhibin, ER, PR | CD56, CD99 | cytokeratin, EMA, CD10, HMB45, S-100, calretinin, CD34, CD117, Dog-1 | 10 | ND | ND |
Zong et al. [6] | 2014 | 5 | 39 | Left | 10 × 7 × 4 | CA125(41), HCG(-) | 3–5 | TAH, LSO, OMT, LD | - | CD99, CK, SMA, vimentin, ER, PR, S-100 | - | CD10, CK7, EMA, desmin | 10 | 66 | NED |
This case | 2015 | 6 | 36 | Right | 6 | CEA(-), CA125(-), CA199(-), SCC(-), HCG(-), AFP(-) | 10 | RSO | - | vimentin, PR, CD10, CD56, WT1 | α-inhibin | AE1/AE3, ER, calretinin, EMA | 8.7 | 6 | NED |